Published in AIDS Weekly, September 18th, 2000
"The potential contribution of a plasmid DNA construct to vaccine-elicited protective immunity was explored in the SIV/macaque model of AIDS," wrote M.A. Egan and colleagues, Wyeth Lederle Vaccines & Pediatrics, New York. "Making use of soluble major histocompatibility class I/peptide tetramers and peptide-specific killing assays to monitor CD8+ T-lymphocyte responses to a dominant SIV Gag epitope in genetically selected rhesus monkeys, a codon-optimized SIV gag DNA vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2000-09-18)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.